| |
Success or failure of a therapeutic program will depend on the understanding of the market and ability to develop an effective commercial strategy. Download our checklist to gain these insights and learn how Premier Consulting can evaluate the market and maximize the potential of your program throughout the development lifecycle.
|
|
Today’s Big NewsJun 4, 2024 |
|
September 30- October 1, 2024| Boston, MA The Fierce New Product Planning Summit is the only conference focused on how life science professionals make informed, value-based, data-driven decisions about pipeline products. Experts gather annually to discuss resource utilization and key questions for commercial success. Stay Updated!
|
|
| By Gabrielle Masson A new trend has emerged at this year’s American Society of Clinical Oncology conference: the possibility of replacing decades-old chemotherapy with novel approaches. AbbVie wants to "be part of that wave." |
|
|
|
By Annalee Armstrong Annexon’s monoclonal antibody ANX005 reduced disability in patients with the rare autoimmune disorder Guillain-Barré syndrome, meeting the main goal of a phase 3 trial. |
By Nick Paul Taylor Alkermes has shown more of the data that persuaded it to throw money at its narcolepsy program. The phase 1b readout suggests Alkermes’ ALKS 2680 can hold its own against Takeda’s rival prospect despite being administered less frequently. |
Sponsored by Altasciences Discover the increasing body of evidence that supports the use of miniature swine as a viable non-rodent option for nonclinical studies. |
By Annalee Armstrong Merck KGaA is hoping to sprout some new oncology and immunology therapeutics with Biolojic Design’s AI-driven drug discovery engine. |
By Annalee Armstrong A clinical research company has pleaded guilty and agreed to pay a record $35 million fine to resolve an animal welfare case that involved the seizure of more than 4,000 beagles in 2022. |
By Helen Floersh Women have long shouldered the burden of birth control. Now, men may soon have an option that is not only hormone-free, but also allows space between doses. |
By Annalee Armstrong The Australian and New Zealand life sciences sector will get a nice boost from a new A$270 million ($180 million) fund from venture capital firm Brandon Capital. |
By Angus Liu After Akeso and Summit's ivonescimab beat Keytruda in a head-to-head trial in non-small cell lung cancer, analysts are trying to sort out the financial ramifications while biopharma insiders are eager to see the exact data. But what does Merck think? |
By Conor Hale The company’s board of directors has approved the plan for Grail to join the Nasdaq, under the ticker “GRAL,” before the end of this month. |
By Angus Liu Following fellow immunotherapy regimens by Roche and AstraZeneca, Bristol Myers Squibb’s Opdivo and Yervoy want to carve out a piece of the first-line liver cancer market, too. |
By Emma Beavins A union organization for nurses nationwide says the deployment of AI in healthcare will push nurses out of patient rooms and compromise patient safety. A new AI Bill of Rights lays out nurse and patient protections, which are not currently being met. |
By Conor Hale A clinical study found that an at-home test based on the DNA found in spit samples could detect cases of prostate cancer that would otherwise slip past a standard blood draw. |
Fierce podcastsDon’t miss an episode |
| | In this week's episode of "The Top Line," two journalists from the Fierce Biotech team share key insights from their four-part series on the challenges and breakthroughs in cell therapy. |
|
|---|
|
|
|
July 8-9, 2024 | Jersey City, NJ Hear the latest industry trends from leaders in the field, and developed input from our esteemed advisory board, to ensure you have a sound plan for your company, brands, and yourself. Save $200 when you register today!
|
|
| WhitepaperNew molecular formats are gaining momentum in today’s market. Characterizing these products and developing robust manufacturing processes can help to usher them to market and provide new treatment options for diseases which are currently challenging to treat. Read this white paper to learn more. Presented by: Lonza |
| WhitepaperThis detailed case study shows how Fresenius Medical Care achieved 25 times faster insights to help kidney disease patients, launching the world’s largest global database of dialysis care with fully anonymized patient data. Sponsored by: Privacy Analytics, an IQVIA company |
| eBookTo make every rare disease trial count, we design patient-centric, relevant strategies for sponsors and caregivers to produce impactful results every time. Sponsored by: Emmes Company |
| WhitepaperThis paper outlines the challenges, pitfalls, & solutions associated with adding rare disease therapies to a biopharma company’s portfolio. Sponsored by: AIM, the strategic leader in life science supply chains |
On Helix Date: 4 July 2024 - Location: Babraham Research Campus, Cambridge UK |
|
| |
|
